

Subject Index

A

- Adrenergic receptor blockade 8: 110–111
β-adrenergic receptor blocking drugs
 adrenergic receptor blockade 8: 110–111
 alcohol withdrawal 8: 117–118
 anxiety states 8: 112–117
 morbid anxiety 8: 112–116
 physiological anxiety 8: 117
 drug dependence 8: 118–120
 hypertension 8: 85
 lithium-induced tremor 8: 121
 psychiatry 8: 111–112
 schizophrenia 8: 120–121
 side-effects 8: 121–124
 beta-blocking drugs 8: 117–118
Alfathein 8: 87–88
 animal studies 8: 99–102
 anaesthetic properties 8: 99–100
 dysmorphology studies 8: 102
 effect on central nervous system 8: 101
 effect on veins 8: 100–101
 haemodynamic effects 8: 100
 hormonal effects 8: 101
 interaction with other anaesthetics 8: 101–102
 clinical pharmacology 8: 93–99
 anaesthetic effect 8: 93–94
 analgesic effect 8: 98–99
 cardiovascular effects 8: 94–96
 effect on muscle 8: 94
 effect on veins 8: 97
 respiratory effects 8: 96–97
 use with other anaesthetics 8: 97
 clinical studies 8: 88–93
 cardioversion 8: 93
 dental anaesthesia 8: 92
 induction of anaesthesia 8: 89–90
 intra-ocular surgery 8: 92–93
 obstetrics 8: 93
 psychiatry 8: 92
 sole anaesthetic agent 8: 90
 dosage 8: 106
 pharmacokinetic studies: animal 8: 102–103
 distribution 8: 102–103
 excretion 8: 103
 metabolism 8: 103
 plasma levels 8: 102
 protein binding 8: 103
 pharmacokinetic studies: human 8: 99
 precautions 8: 105
 side-effects 8: 82, 104–105, 153
Alphadolone acetate
 combined with alfaxalone 8: 87–106
Alfaxalone
 combined with alphadolone acetate 8: 87–108
Althesin
 sic alfathein
Anaemia, aplastic
Drug-induced 8: 147–148
Anaesthesia
 alfathein 8: 87–106
 in hypertension 8: 84–86
 Anaesthesia: dental
 alfathein 8: 92
Anaesthetics
 side-effects 8: 81–83
Anaesthetics: intravenous
 alfathein 8: 87–108
 sevoflurane 8: 153–155
 side-effects 8: 82–83
Antidepressants, tricyclic
 use in elderly 8: 134
Anxiety
 beta-blocking drugs 8: 112–116

Subject Index

A

- Adrenergic receptor blockade 8: 110–111
β-adrenergic receptor blocking drugs
 adrenergic receptor blockade 8: 110–111
 alcohol withdrawal 8: 117–118
 anxiety states 8: 112–117
 morbid anxiety 8: 112–116
 physiological anxiety 8: 117
 drug dependence 8: 118–120
 hypertension 8: 85
 lithium-induced tremor 8: 121
 psychiatry 8: 111–112
 schizophrenia 8: 120–121
 side-effects 8: 121–124
 beta-blocking drugs 8: 117–118
Alfathein 8: 87–88
 animal studies 8: 99–102
 anaesthetic properties 8: 99–100
 dysmorphology studies 8: 102
 effect on central nervous system 8: 101
 effect on veins 8: 100–101
 haemodynamic effects 8: 100
 hormonal effects 8: 101
 interaction with other anaesthetics 8: 101–102
 clinical pharmacology 8: 93–99
 anaesthetic effect 8: 93–94
 analgesic effect 8: 98–99
 cardiovascular effects 8: 94–96
 effect on muscle 8: 94
 effect on veins 8: 97
 respiratory effects 8: 96–97
 use with other anaesthetics 8: 97
 clinical studies 8: 88–93
 cardioversion 8: 93
 dental anaesthesia 8: 92
 induction of anaesthesia 8: 89–90
 intra-ocular surgery 8: 92–93
 obstetrics 8: 93
 psychiatry 8: 92
 sole anaesthetic agent 8: 90
 dosage 8: 106
 pharmacokinetic studies: animal 8: 102–103
 distribution 8: 102–103
 excretion 8: 103
 metabolism 8: 103
 plasma levels 8: 102
 protein binding 8: 103
 pharmacokinetic studies: human 8: 99
 precautions 8: 105
 side-effects 8: 82, 104–105, 153
Alphadolone acetate
 combined with alfaxalone 8: 87–106
Alfaxalone
 combined with alphadolone acetate 8: 87–108
Althesin
 sic alfathein
Anaemia, aplastic
Drug-induced 8: 147–148
Anaesthesia
 alfathein 8: 87–106
 in hypertension 8: 84–86
 Anaesthesia: dental
 alfathein 8: 92
Anaesthetics
 side-effects 8: 81–83
Anaesthetics: intravenous
 alfathein 8: 87–108
 sevoflurane 8: 153–155
 side-effects 8: 82–83
Antidepressants, tricyclic
 use in elderly 8: 134
Anxiety
 beta-blocking drugs 8: 112–116

treatment in elderly 8: 136

Aplastic anaemia

see anaemia, aplastic

Azathioprine

hepatitis 8: 141

B

Biliary tract disease

corticosteroids 8: 145

Butyrophenones

use in elderly 8: 135–136

C

Cardioversion

alfathesin 8: 93

Chloroquine

porphyria cutanea tarda 8: 152

Cholangiohepatitis

corticosteroids 8: 145

Cirrhosis

corticosteroids 8: 144

Corticosteroids

clinical use

biliary tract disease 8: 145

cholangiohepatitis 8: 145

cholestrasis 8: 139–140

chronic hepatitis 8: 140

cirrhosis 8: 144

drug-induced liver disease 8: 144

extrahepatic obstruction 8: 145

fulminant hepatitis 8: 140

hepatitis, active chronic 8: 140–143

liver disease 8: 139–145

viral hepatitis 8: 139

D

Dental anaesthesia see anaesthesia: dental

Depression

treatment in elderly 8: 134

Drug dependence

beta-blocking drugs 8: 118–120

Drug-induced disease

aplastic anaemia 8: 147–148

Drug reactions, adverse

alfathesin 8: 104–105, 153

anaesthetics 8: 81–83, 153–157

beta-blocking drugs 8: 121–124

halothane 8: 81–82, 155–157

pentazocine 8: 149–150

rifampicin 8: 148–149

E

Eclampsia 8: 129–130

Elderly

psychotherapeutic drugs 8: 132–138

G

Geriatric pharmacology

psychotherapeutic drugs 8: 132–138

H

Hagmolytic

due to rifampicin 8: 148–149

Halofenate

uricosuric action 8: 146

Halothane

jaundice 8: 81–82, 155–157

Heparin

prevention of thrombosis 8: 152–153

Hepatitis

corticosteroids 8: 140–143

Hepatotoxicity

halothane 8: 81–82, 155–157

Hydrocortisone

fulminant hepatitis 8: 140

Hypertension

anaesthesia 8: 84–86

in pregnancy 8: 125–131

detection 8: 125–126

eclampsia 8: 129–130

labour 8: 130–131

management 8: 126–129

when to hospitalise 8: 126

Hypnotic drugs

use in elderly 8: 136–137

I

Immunosuppressive drugs

liver disease 8: 139–145

Insomnia

treatment in elderly 8: 136–137

K

Ketamine

compared with alfathesin 8: 95–96

L

Lithium

side-effects

beta-blocking drugs 8: 121

use in elderly 8: 134–135

Liver disease

treatment with corticosteroids 8: 139–145

M

Mania

treatment in elderly 8: 134–135

Methohexitone

- compared with alfathesin 8: 90, 92, 95, 97
Methotrexate
effect on liver 8: 151
psoriasis 8: 151
- O**
- Obstetrics**
alfathesin 8: 93
- P**
- D-Penicillamine**
scleroderma 8: 157
- Pentazocine**
central nervous system effects 8: 149–150
colonic response 8: 150–151
side-effects 8: 149–150
- Phenothiazines**
use in elderly 8: 135–136
- Porphyria cutanea tarda**
chloroquine 8: 152
- Practolol**
psychiatry 8: 109–124
- Prednisolone**
hepatitis 8: 140–141
- Pregnancy**
hypertension 8: 125–131
- Propanidid**
compared with alfathesin 8: 90, 97
side-effects 8: 82, 154
- Propranolol**
psychiatry 8: 109–124
- Proteinuria**
in pregnancy 8: 127
- Psoriasis**
methotrexate 8: 151
- Psychiatric disorders**
in the elderly 8: 133
- Psychiatry**
alfathesin 8: 92
- Psychotherapeutic drugs**
use in the elderly 8: 132–138
anxiety states 8: 136
depression 8: 134
general principles 8: 132–133
insomnia 8: 136–137
mania 8: 134–135
organic psychoses 8: 136
schizophrenia 8: 135–136
- R**
- Rifampicin**
side-effects 8: 148–149
- S**
- Schizophrenia**
beta-blocking drugs 8: 120–121
treatment in elderly 8: 135–136
- Scleroderma**
D-penicillamine 8: 157
- Skin cancer**
see cancer, skin
- Sotalol**
psychiatry 8: 109–124
- T**
- Thiopentone**
compared with alfathesin 8: 88–90, 93, 95, 97
side-effects 8: 82–83
- Thrombosis**
prevention after myocardial infarction 8: 152–153
- Tremor**
beta-blocking drugs 8: 121
- U**
- Uricosuric action**
halofenate 8: 146

Modern Problems of Pharmacopsychiatry

Series Editors: *Th.A. Ban* (Montreal, Que.), *F.A. Freyhan* (Washington, D.C.),
P. Pichot (Paris) and *W. Pöldinger* (Vienna)

Vol. 9 Trazodone

Proceedings of the First International Symposium, Montreal 1973

Volume Editors: *Th.A. Ban* (Montreal, Que.) and

B. Silvestrini (Rome)

VI + 210 p., 86 fig., 83 tab., 1974

SFr. 75.- / US \$ 27.50 / DM 71.- / £ 10.90

ISBN 3-8055-1718-1

List of Contributors:

B. Silvestrini, V.G. Longo and A. Scotti de Carolis (Rome), *K. Yamatsu, T. Kaneko, Y. Yamanishi, A. Kitahara and S. Ohtake* (Tokyo), *J.R. Boissier, E. Portmann-Cristesco, P. Soubré and J. Fichelle* (Paris), *S. Garattini* (Milan), *G.L. Gatti* (Rome), *E.F. Domino* (Ann Arbor, Mich.), *T. Fujita, C. Yamato and T. Takahashi* (Tokyo), *L. Angelucci and P. Bolle* (Rome), *K.F. Rivett* (Huntingdon), *P. Scorsa Barcellona* (Rome), *Y. Suzuki* (Tokyo), *Th.A. Ban, M.M. Amin, N.P.V. Nair and F. Engelsman* (Montreal, Que.), *F. Antonelli, M. De Gregorio, A. Dionisio and D. Peruzy* (Rome), *S. Miura* (Sagamihara), *D. Schwarz and M. Blendl* (Munich), *A. Lopez Zanon* (Madrid), *R. Montanini* (Varese), *G. Gunella* (Bologna), *Y. Shibahara* (Kyoto), *F. Pariente, A. Muratorio, C. Maggini, G. Coccagna and M. Guazzelli* (Pisa), *A. Agnoli, M. Piccione, M. Casacchia and C. Fazio* (Rome), *G.B. Cassano, P. Castrogiovanni and L. Conti* (Pisa), *J. Saarma* (Tartu, USSR)

Recent advances in psychopharmacotherapy seem to follow established avenues of specific substances belonging to well-known groups. New avenues can only be opened and explored through original molecules totally unrelated to known chemical families of psychoactive usefulness. Trazodone appears to be such a novelty and the International Symposium held in Montreal on October 5 and 6, 1973 confirms the importance of this new substance both from a point of view of applied therapeutic sciences as well as scientific research. The publication of the proceedings of this Symposium may represent a major contribution to the knowledge of modern psychopharmacotherapy.



S. Karger · Basel · München · Paris · London · New York · Sydney

General Information

Publication data: Two volumes of *Drugs* are published annually. Each volume comprises six 80-page issues. Subscription price per volume SFr. 135. - / US \$49.00 / DM128. - / £19.60 including postage. Multiple subscription rates on request. *Drugs* is published by Australasian Drug Information Services Pty. Ltd., 559 Sydney Road, Seaforth, N.S.W. Australia.

Subject index: Each issue has its own comprehensive subject index which is cumulated in issue No. 6 of the second volume in each year.

Editorial matter is prepared by our own professionally qualified editorial staff and by honorary specialist consultants from all fields of medicine. While great care has been taken in compiling and checking the information contained in *Drugs*, the publisher cannot accept any responsibility for errors or omissions. The inclusion or exclusion of any product does not mean that the publisher advocates or rejects its use either generally or in any particular field or fields.

Drug nomenclature: Approved names of the British Pharmacopoeia Commission are used throughout the text. When the Commission has not adopted a name for the drug under discussion, the United States Adopted Name (USAN - United States Pharmacopeial Convention Inc) or the International Non-Proprietary Name (INN - WHO) is used. When available, all three names are given at the head of the evaluations on new drugs and review article sections, and elsewhere in the text as appropriate. Other synonyms (e.g. research code names of new drugs) are also given.

Correspondence: Letters to the editor are welcomed. They should be submitted in duplicate type-written on one side of the paper only and double-spaced with a wide margin. They should be of reasonable length and written in English. Letters will be published if found suitable and will be subject to editorial review and possible abridgement.

Manuscripts: Information on the preparation of manuscripts will be provided to authors.

Copyright © 1974 Australasian Drug Information Services Pty Limited. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying or recording or by any information storage and retrieval system, without permission in writing from the publishers.

Subscription

Subscription orders can be placed with any bookstore or direct with the distributors S. Karger AG, Arnold-Böcklin-Strasse 25, CH-4011 Basel (Switzerland), or else with the following:

Subscription Order Form					
Please enter my subscription for <i>Drugs</i> beginning with					
<input type="checkbox"/> Vol. 1, 1971 <input type="checkbox"/> Vol. 4, 1972 <input type="checkbox"/> Vol. 7, 1974					
<input type="checkbox"/> Vol. 2, 1971 <input type="checkbox"/> Vol. 5, 1973 <input type="checkbox"/> Vol. 8, 1974					
<input type="checkbox"/> Vol. 3, 1972 <input type="checkbox"/> Vol. 6, 1973					
Name					
Title					
Address					
City					
State/Zip					

Bundesrepublik Deutschland:
S. Karger GmbH, Postfach 2,
D-8034 Germerring/München

France: S. Karger S.A., 42bis, Bd de
La Tour-Maubourg, F-75 Paris 7e

Great Britain: John Wiley and Sons
Ltd., Baffins Lane, Chichester, Sussex

USA: Albert J. Phiebig Inc.,
US Representative of S. Karger, P.O.
Box 352, White Plains, NY 10602

Australia: Australasian Drug
Information Services Pty. Ltd., Agents
in Australasia for S. Karger, P.O. Box
194, Balgowlah/Sydney, NSW 2093

New Zealand: Australasian Drug
Information Services Pty. Ltd.,
New Zealand Office, P.O. Box 34-030,
Birkenhead, Auckland 10

